| 04/22/2026 2:24 PM | Actuate Therapeutics (1652935) Subject Voss Capital, LP (1730145) Filed by | Form SCHEDULE 13G/A | |
| 04/09/2026 3:04 PM | Actuate Therapeutics (1652935) Filer | Form ARS | |
| 04/06/2026 3:06 PM | Actuate Therapeutics (1652935) Filer | Form DEFA14A | |
| 04/01/2026 4:19 PM | Actuate Therapeutics (1652935) Issuer LYTLE PAUL J (1244110) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 4:19 PM | Actuate Therapeutics (1652935) Issuer Mazar Andrew Paul (1727393) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 4:19 PM | Actuate Therapeutics (1652935) Issuer SCHMITT DANIEL M (1318470) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 5:10 PM | Actuate Therapeutics (1652935) Issuer SCHMITT DANIEL M (1318470) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 3:00 PM | Actuate Therapeutics (1652935) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/07/2026 11:45 AM | Actuate Therapeutics (1652935) Issuer Kairos Venture Partners II, L.P. (1696711) Reporting THOMSON TODD S (1225707) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/17/2025 11:25 AM | Actuate Therapeutics (1652935) Subject Voss Capital, LP (1730145) Filed by | Form SCHEDULE 13G | |
| 12/11/2025 3:22 PM | Actuate Therapeutics (1652935) Subject Kairos Venture Partners II, L.P. (1696711) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for ACTU and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 11/28/2025 4:19 PM | Actuate Therapeutics (1652935) Filer | Form 424B5 | |
| 11/28/2025 4:21 PM | Actuate Therapeutics (1652935) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/21/2025 3:30 PM | Actuate Therapeutics (1652935) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/13/2025 3:00 PM | Actuate Therapeutics (1652935) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 09/10/2025 4:05 PM | Actuate Therapeutics (1652935) Filer | Form 424B5 | |
| 09/10/2025 4:11 PM | Actuate Therapeutics (1652935) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/08/2025 11:15 PM | Actuate Therapeutics (1652935) Filer | Form EFFECT | |
| 08/04/2025 11:15 PM | Actuate Therapeutics (1652935) Filer | Form EFFECT | |
| 07/25/2025 3:00 PM | Actuate Therapeutics (1652935) Filer | Form S-1 Registration statement under Securities Act of 1933 | |
| 07/07/2025 3:37 PM | Actuate Therapeutics (1652935) Filer | Form D Notice of Exempt Offering of Securities | |
| 06/30/2025 12:01 PM | Actuate Therapeutics (1652935) Issuer BIOS Actuate Co-Invest I, LP (1771378) Reporting BIOS Actuate Co-Invest II, LP (1825398) Reporting Bios Actuate Co-Invest III, LP (1956704) Reporting BIOS Advisors GP, LLC (1813844) Reporting BIOS Capital Management, LP (1813845) Reporting BIOS Equity Partners III, LP (1831976) Reporting BIOS Fund III NT, LP (1791910) Reporting BIOS Fund III QP, LP (1791916) Reporting BIOS Fund III, LP (1791917) Reporting Fletcher Aaron G.L. (1789490) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2025 12:02 PM | Actuate Therapeutics (1652935) Issuer Bios Equity Partners II, LP (1813313) Reporting Bios Equity Partners, LP (1813314) Reporting BIOS Fund I QP, LP (1700297) Reporting BIOS Fund I, LP (1697316) Reporting BIOS Fund II NT, LP (1728851) Reporting BIOS Fund II QP, LP (1716869) Reporting BIOS Fund II, LP (1714576) Reporting Cavu Advisors, LLC (1813310) Reporting Cavu Management, LP (1813270) Reporting Kreis Leslie W. (1813316) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2025 12:03 PM | Actuate Therapeutics (1652935) Issuer Bios 2024 Co-Invest, LP (2028708) Reporting Bios Clinical Opportunity Fund, LP (1988639) Reporting Bios Equity COF, LP (2000747) Reporting BP Directors, LP (1813311) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2025 11:08 AM | Actuate Therapeutics (1652935) Subject BIOS Fund I, LP (1697316) Filed by | Form SCHEDULE 13D/A | |
| 06/26/2025 7:11 AM | Actuate Therapeutics (1652935) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/05/2025 1:57 PM | Actuate Therapeutics (1652935) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/02/2025 6:40 AM | Actuate Therapeutics (1652935) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/27/2025 3:15 PM | Actuate Therapeutics (1652935) Subject BIOS Fund I, LP (1697316) Filed by | Form SCHEDULE 13D/A | |
| 05/23/2025 3:37 PM | Actuate Therapeutics (1652935) Issuer THOMSON TODD S (1225707) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/23/2025 3:05 PM | Actuate Therapeutics (1652935) Issuer RONNEBERG AMY L (1380292) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/23/2025 3:05 PM | Actuate Therapeutics (1652935) Issuer Keyes Jason A (1678152) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/23/2025 3:05 PM | Actuate Therapeutics (1652935) Issuer Fletcher Aaron G.L. (1789490) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/23/2025 3:05 PM | Actuate Therapeutics (1652935) Issuer Zabrowski Dan (1940818) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/23/2025 3:05 PM | Actuate Therapeutics (1652935) Issuer Sawhney Roger (1858748) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/06/2025 7:09 AM | Actuate Therapeutics (1652935) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |